Fibrogen, Inc.
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded as renamed to Kyntra Bio, Inc. (2026)
4
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 11 to 25, 2027 · next Feb 11
- 1 fee due Apr 6, 2027The maintenance fee for Thiochromene derivatives as HIF hydroxylase inhibitors (US 9,149,476) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Methods for Treating Idiopathic Pulmonary Fibrosis (US 10,555,713) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,174,976 | Cyanoisoquinoline compounds and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,952,160 | Isothiazole-Pyridine Derivatives as Modulators of Hif (Hypoxia Inducible Factor) Activity In force · High confidence | In force | High confidence | |
| US 9,149,476 | Thiochromene derivatives as HIF hydroxylase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,927,591 | Thiochromene Derivatives as Hif Hydroxylase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,102,721 | Therapeutic method In force · From the USPTO record | In force | From the USPTO record | |
| US 9,115,356 | Connective Tissue Growth Factor Antisense Oligonucleotides In force · High confidence | In force | High confidence | |
| US 10,555,713 | Methods for Treating Idiopathic Pulmonary Fibrosis In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 19 patents in force now held by others · 26 lapsed for an unpaid fee · 50 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 abandoned · 64 no status recorded